1
Q
what causes microcytic anaemia
A
iron deficiency
thalassaemia
2
Q
what causes normocytic anaemia
A
acute haemorrhage
anaemia of chronic disease
- chronic inflammationa
- chronic infection
- malignancy
- inc ferritein
aplastic anaemia (bone marrow failure)
- idiopathic
- Fanconi’s anaemia
- hepatitis - treatment induced
- drugs eg NSAIDs
Haemolytic anaemia
3
Q
what causes macrocytic anaemia
A
megaloblastic (large, structurally abnor, immature cells)
- Vit B12 deficiency
- folate deficiency
Non-megaloblastic
- pregnancy
- alcohol
4
Q
what value of MCV is microcytic anaemia
A
MCV < 80
5
Q
what value of MCV is macrocytic anaemia
A
MCV > 100
6
Q
defintion of anaemia?
A
- Men Hb < 130
- Non-pregnant women >15 yrs old – HB < 120
- pregnant women HB < 110 throughout pregnancy
- postpartum - < 100
7
Q
aetiolgy of IDA
A
- Dietary deficiency - really of course on its own
- malabsorption Coeliac disease, H pylori, achlorhydria (absence of hydrochloric acid in the stomach), pica, hiatal hernia
- Chronic blood loss – GI loss, menstruation, UC
- increase requirement – menstruation, pregnancy
- Other courses : blood donation, self-harm, nosebleed and NSAIDs, aspirin, parasites, hookworms
- Iron is absorbed in a duodenum and an upper jejunum
- IDA is not an end diagnosis and will need further investigation
- blood loss = most common cause of IDA
8
Q
symptoms of IDA
A
fatigue palpitations dyspnoea cognitive dysfunction restless leg syndrome vertigo tinnitus puritis score tongue pica - abnor dieary craving eg dirt
9
Q
signs of IDA
A
angular cheilosis
pallor
atrophic glossitis (smooth glossy tongue)
dry rough skin and damaged hair
hair loss
koilonychia
systolic flow murmur
heart failure
10
Q
ix for IDA
A
- FBC low haemoglobin
- MCV < 80
- MCH (mass per cell)< 27.5
- MCHC (HB conc. per cell) – low
- reticulocyte count (amount of youngest blood cells present)
- blood film microcytic + hypochromic cells
- serum ferritin – dec (< 15 = diagnostic)
- serum iron low
- total iron-binding capacity (TIBC) – inc
- transferrin saturation (serum iron x 100/TIBC) – low
- coeliac serology
- H.pylori testing
- IBD screening
11
Q
mx of IDA
A
• address underlying cause
o Stop NSAIDs
o treat H.pylori
o treat menorrhagia
o maintain and adequate balanced intake of iron rich food – dark green vegetables, meat, apricots)
• oral ferrous sulfate 200mg table BD/TDS continue for 3 months after iron deficiency is corrected to allow iron stores to be replenished
o SE – constipation, diarrhoea, black stool
o can also add ascorbic acid (to help absorb non-haem iron in plants and diary required asset for digestions of iron)
• consider transfusion if symptomatic at rest
12
Q
definition of acute non-haemolytic reactions during transfusion
A
• And that first reaction to a blood transfusion which is not because of blood group incompatibility
• can be acute (24 hours) or delayed
•
13
Q
what are the different types of acute non-haemolytic reactions during transfusion
A
o anaphylaxis
o Bacterial contamination
o Lung Transfusion related acute lung injury (TRALI), Transfusion associated circulatory overload (TACO), Transfusion Associated Dyspnoea (TAD)
o Febrile non-haemolytic transfusion reaction
14
Q
which type of acute non-haemolytic reactions (ANHRT) during transfusion is the most common
A
TRALI
15
Q
pathophysiology of TRALI
A
occurs as a result of granulocyte activation in the pulmonary vasculture –> resulting in inc vascular permeability
16
Q
clinical features of anphylactic reaction in ANHRT
A
- Allergic reaction when patient has antibodies that react with proteins in the transfused blood
- Occurs when a person has been previously sensitised to an allergen present in blood and on re-exposure, release immunoglobulins (IgE and IgG antibodies)
- Occurs within 15 minutes
- Dyspnoeic (bronchospasm and laryngeal odema), chest pain, abdominal pain and nausea, urticaria, hypotension, angioedema, tongue swelling, wheeze
17
Q
clinical features of bacterial contamination in ANHRT
A
- Infective shock
- Occurs within 15 minutes
- Acute onset hypertension or hypotension, rigors and collapse
18
Q
clinical features of TRALI in ANHRT
A
ARDS due to donor plasma containing antibodies against patient’s leukocytes
occurs within 6 hours
sudden dyspnoea, prominent non-productive cough, hypoxia, can have frothy sputum
fever and rigors
hypotension
CXR - bilateral infiltration
19
Q
clinical features of TACO in ANHRT
A
occurs within 6 hours
- sudden dyspnoea
- hypoxemia
- raised BP/JVP
20
Q
clinical features of TAD in ANHRT
A
breathing difficulties because of blood products - not hypertension/hypotenison
21
Q
clinical features of febrile non-haemolytic transfusion reaction in ANHRT
A
• Fever and rigors during RBC and platelet transfusion due to platelet antibodies to transfused white cells.
22
Q
investigation for ANHRT
A
FBC, U&Es, LFT, coag screen
first urine sample (haemoglobin)
repeat G&S
IgA level –> needs pre and post transfusion sample
serial mast cell tryptase at ime 0, 3, 24 horus
blood cultures
consider CXR if hypoxia
blood gases with hypoxia
23
Q
mx for bacterial contamination in ANHRT
A
stop transfuison
FBC + bloodcultures
supportive measures - O2, fluid, consider ionotropic support if BP consistentialy low
- Start broad spectrum abx + follow local SEPSIS pathway
- Refer to haematology/ intensive care unit.
24
Q
mx for anaphylactic reactions in ANHRT
A
- Follow anaphylaxis guidelines
- IM Adrenaline (epinephrine) 500 micrograms 1: 1000 intramuscularly (IM) and repeat every 5 minutes
- 10mg IV Chlorphenamine and 200mg IV hydcortisone
- Oxygen, fluids, salbutamol nebulisers (if required)
- Call anaesthetist if difficulty maintaining the airway
25
mx for TRALI in ANHRT
* Stop transfusion
* Seek expert advice immediately
* Oxygen, fluids, inotropes (as for acute respiratory distress syndrome)
* Monitor blood gases and serial CXR
26
mx for TACO in ANHRT
• Assess patient and slow or stop transfusion
• Treat as for HF: Oxygen + IV furosemide
TAD
27
mx for TAD in ANHRT
* Assess patient and slow or stop transfusion
| * Symptomatic management.
28
mx Febrile non-haemolytic transfusion reaction for in ANHRT
* Assess patient and Stopping/ slowing transfusion
| * paracetamol
29
what are the 2 main types of macrocytic anaemia
megaloblastic
- B12 and folate deficiency
non-megaloblastic
- liver disease, alcohol, hypothyroidism
30
how is B12 absorbed in the body
B12 released from food in the stomach by peptic acid parietal cells at the gastric fundus produce intrinsic factors intrinsic factors binds B12 to form a complex travels to the terminal ileum binds to transcobalamine (made in liver) blood stream
31
aetiology of Vit B12 anemia
pernicious anemia, HIV, diet deficiency, Crohn's
drugs - metformin, PPI, H2 recepor antagonist, anticonvulsant
32
aetiology of folate deficiency leading to anaemia
malabsoprtion, dietary dificiency
drug - trimethoprim/nitrifurantoin
33
clinical features of macrocytic anaemia
* Typically, asymptomatic
* symptoms of anaemia dyspnoea, pallor, lethargy, petechiae, glossitis, angular chilitis, cognitive impairment
• B12 (present as neuropsychiatric, peripheral neuropathy and haematological
o paraesthesia, ataxia, loss of vibration sensation
o peripheral neuropathy
o subacute degeneration of the spinal cord – triad of upgoing planters, loss of knee jerk, loss of ankle jerk
o Romberg’s test loss of proprioception
```
• Folate
o prolonged diarrhoea
o headache
o loss of appetite and weight loss
o tachycardia
o tachypnoea
o heart murmur
o signs of heart failure
o signs of chronic alcohol abuse
```
34
investigation for macrocytic anaemia
* FBC low Hb, high MCV/MCH
* blood film hyper-segmented, polymorphonucleated cells + oval macrocytes
* serum B12/folate – dec
* serum cobalamin (cobalamin = B12, diagnostic marker for Vit B12 deficiency) dec
* serum methylmalonic acid (inc in Vit B12 deficiency) & homocysteine (inc in B12, folate and hypothyroidism) elevated
* reticulocyte count used to differentiate between B12 deficiency from haemolytic anaemia
* intrinsic factor antibody used to differentiate between Vit B12 deficiency or pernicious anaemia +ve if pernicious anaemia
* antiparietal cell antibody used to differentiate between Vit B12 deficiency or pernicious anaemia +ve if pernicious anaemia
* LFT, GGT, TFT – identify causes
35
management for macrocystic anaemia
If Neurological involvement
• Seek urgent hematology advice
• If expert advice unobtainable give hydroxocobalamin 1 mg intramuscularly on alternate days until there is no further improvement, then administer hydroxocobalamin 1 mg intramuscularly every 2 months.
No-neurological invovlment
Initial
• Initially administer hydroxocobalamin 1 mg intramuscularly 3 times a week for 2 weeks
Maintenance
• Non-diet related; administer hydroxocobalamin 1 mg intramuscularly every 2–3 months for life.
• Diet related: oral cyanocobalamin tablets 50–150 micrograms daily between meals, or have a twice-yearly hydroxocobalamin 1 mg injection. + dietary advice (eggs, meat, milk and dairy, salmon)
36
complication of B12 deficiency
o Loss of cutaneous sensation, lots of mental and physical drive, muscle weakness, optic neuropathy, psychiatric disturbance (mild neurosis to severe dementia)
o symmetrical neuropathy affecting the legs more than the arms - usually present with ataxia or paraesthesia
o urinary or faecal incontinence
37
Definition of haemolytic anaemia
• a number of conditions resulting to premature destruction of RBCs
38
what are the different types haemolytic anaemia
inherited --> membrane effects, abnor HB production, enzyme defects
acquired --> immune/non-immune
39
clinical features of haemolytic anaemia
* Anaemia symptoms: SOB, palpitations, tachycardia, angina, pallor, fatigue, light-headedness
* Splenomegaly: spleen becomes filled with destroyed RBC
* Jaundice: bilirubin release from RBC destruction
* Episodic dark urine haemoglobinuria suggestive of paroxysmal nocturnal haemoglobinuria
40
Ix for haemolytic anaemia
* FBC low Hb & normocytic
* MCHC inc in spherocytes and reticulocytes
* reticulocyte count inc
* blood film identifies causes eg if spherocytosis and elliptocytosis
* LDH LDH inc + dec haptoglobin = 90% chance of haemolytic anaemia
* hepatoglobin (binds to free HB) low
* direct coombs’ test (detect IgG or complement bound to RBC cell surface) +ve autoimmune haemolytic anaemia
* inc bilirubin and urobilinogen
41
Mx of haemolytic anaemia
* administer folic acid due to risk of deficiency
* discontinue medications that may precipitate or aggravate haemolysis.
* Avoid transfusion unless necessary
* Iron therapy may be indicated for intravascular causes
* Autoimmune haemolytic therapy: corticosteroid or rituximab + intravenous immunoglobulin (IVIG)
* Splenectomy (remove site of significant antibody production and site for RBC destruction)
* Plasmapheresis – similar to dialysis but for the removal of antibodies in the blood.
42
what cells do lymphoma affect?
B and T lymphocytic cells
43
what cells does Hodgkin's lymphoma affect
B cells only
44
what cells does non- Hodgkin's lymphoma affect
2 words = 2 cells
cab be B or T cells
45
what can cause Burkitt lymphoma
EBV, HIV & malaria
46
symptoms of Burkitt's lymphoma
larg abdo mass and symptoms of bowel obsturction
47
what can cause mucosa associated lymphoid tissue lymphoma (MALT)
H.pylori infection
48
symptoms of MALT?
usually around the sotmahc
49
what is the key symtpom of diffuse large B cell lymphoma
painless rapid growing mass in > 65
50
aetiology of hodgkin lymphoma
unclear, EBV, glandular feer?
51
aetiology of non-hodgkin lymphoma
o HIV, EBV, H.pylori, Hep B/C, exposure to pesticides, FHx, Herpes virus 8
o Sjogren’s syndrome, RA, SLE and coeliac disease
o immunodeficiency state eg post-organ transplant
52
epidemiology of lymphoma
* Hodgkin lymphoma – bimodal age distribution (20 and 75)
| * Non-Hodgkin lymphoma – 5 times as common as Hodgkin lymphoma, common > 50.
53
clinical features of lymphoma
• both Hodgkin/non-Hodgkin
o lymphadenopathy cervical, axilla, inguinal, non-tender and rubbery often alcohol induced pain
o B symptoms cyclic fever, weight loss, night sweats
o fatigue, itching, cough + SOB (mediastinal mass), abdo pain, recurrent infections
o splenomegaly, hepatomegaly, bone marrow infiltration
o SVC syndrome extensive mediastinal adenopathy can compress the SVC leading to dyspnoea, cough, orthopnoea and facial and upper extremity oedema and ilated neck veins
54
what staging is used for lymphoma
Ann arbour staging
55
Ix for lymphoma
o FBC with differentials pancytopenia if bone marrow infiltration
o lymph node biopsy
hodgkin’s lymphoma Reed-sternberg cell
o blood film
non-hodgkin lymphoma nucleated RBC, left shift
o skin biopsy T cells in NHL
o LFTs – LDH (raised) and albumin (low) but nonspecific
o serology for HIV, EBV, Heps virus 8
o CXR/CT/PET/MRI – stage cancer
o bone marrow biopsy – see if bone marrow infiltration took place
o ESR = prognostic factor
56
mx for lymphoma
* chemo +/- radiotherapy for both
| * NHL R-CHOP-21 (rituximab + cyclophosphamide+ doxorubicin + vincristine + prednisolone for 21 days)
57
definition of myeloma
it is cancer of monoclon cells (which is a subtype of B cells that produces immunoglobulin) --> leeds to production and over-secretion of immunoglobulin into serum and urine
58
what is the most common subtype of myeloma
IgG myeloma = most common
59
RF for myeloma
```
? 70 yrs old
male
black
FHx
obesity
```
60
clinical features of myeloma
• Cancerous plasma cells invade the bone marrow.
• This leads to suppression of the development of other blood lines:
o Myeloma bone disease = bone pain
* MM cells secrete osteoclast activating factors → This results in osteolytic lesions → subsequent pathological fractures
* Hypercalcemia: bone resorption from osteoclasts incerasse serum calcium levels.
• Myeloma renal disease
o High levels of immunoglobulins (antibodies) can block the flow through the tubules AND Hypercalcemia hard to clear by the kidneys
o Failing kidney can’t produce EPO (anaemia – fatigue, SOB)
• Raised plasma viscosity (due to high proteins in the blood)
o Easy bruising
o Easy bleeding
• Reduced or loss of sight due to vascular disease in the eye
• Heart failure
• Stroke
61
investigation of myeloma
FBC - normocytic, normomcgromic anaemia, low WBC, low platelets
blood films
U&Es --> kidney is affect, inc Ca2+
ALP - bone involvment
ESR - raised
plasma viscosity
serum/urine electrophoresis - paraprotein spikes (Bence-JOnes protein)
serum free light chain assy - inc conc of free light chain
serum immunoglobulins - elevated
serum albumin - elevated
skeletal survery - osteopenia, osteolytic lesion, pathological fractures
* whole-body, low dose computed tomography (WBLD-CT) osteolytic lesions
* x-ray pepper-pot skull, due to lytic lesions throughout the skull
62
mx for myeloma
```
• MDT – oncology + haemoatology
• 1st line proteasome inhibitors bortezomib
• stem cell transplant
• immunomodulatory drugs
• chemo
• monoclonal antibodies
• symptoms control
o EPO transfusions
o VTE prophylaxis
o bone disease management
Bisphosphonates – reduce osteoclast activity (beware of jaw necrosis – must have dental review prior to starting)
NSAIDS
radio
orthopedi surgery
cement augemntations
```
63
what is DIC
Disseminated Intravascular Coagulation
• A syndrome characterised by the systemic activation of blood coagulation, which generates intravascular fibrin, leading to thrombosis of small and medium sized vessels and eventually organ dysfunction. As clotting factors are exhausted haemorrhages occur.
64
aetiology of DIC
infection
malignancy - leukaemia
trauma
pregnancy related issues --> placental abruption, amniotic fluid embolism, severe hypertension/ eclampsia and HELLP syndrome
incompatible blood group
liver disease
pancreatitis
dissecting aortic aneurysm
65
clinical features. ofDIC
```
• bleeding from at least 3 unrelated sites is typical and likely sites incl
o ear, nose, throat
o GI tract
o resp tract
o site venepuncture
• confusion or disorientation
• fever
• signs of haemorrhage
• signs of ARDS
• skin signs
o Petechiae, Purpura, Haemorrhagic bullae, Acral cyanosis, Skin necrosis, Sings of thrombosis, Localised infarction and gangrene
```
66
ix for DIC
* platelet – low
* prothrombin time – prolonged
* fibrinogen – dec
* D-dimer/fibrin degradation products – elevated
67
mx of DIC
* A-E assessment
* treat underling disorder
* platelet + FFP
68
pathophysiology of Sickle cell Disease
autosomal recessive disease - when gene codes for beta chin of HB is abnormal
69
what are 4 urgent/acute diseases which can occur in Sickle Cell DIsease
• Vaso-occlusive crises (ribs, spine, pelvis)
o Sickle cells clogging capillaries causing distal capillaries
o Pain, dactylitis, fever, priapism (painful and persistent erection)
• Splenic sequestration crisis (MEDICAL EMERGENCY)
o Sickle cells clogging blood flow to the spleen
o Splenomegaly and painful spleen,
o Pooling of blood in the spleen leads to severe anaemia and circulatory collapse.
• Aplastic crisis
o Temporary loss of the creation of new blood cells: triggered by parvovirus B19.
o Anaemia – pallor/fatigue, tachycardia + jaundice (lemon tinge)
• Acute Chest Syndrome (MEDICAL EMERGENCY)
o Fever, chest pain, dyspnoea, tachypnoea
o New filtrates seen on chest x-ray.
70
investigation for Sickle cell disease
* Refer to hematology
* Newborn help prick test at 5 days of age.
* Blood film: sickle cells and target cells
* ↑ bilirubin and reticulocytes
71
management of chronic sickle cell disease
* Avoid triggers for crises e.g. dehydration, cold, infections
* Folic acid, Abx prophylaxis, vaccinations, hydroxycarbamide (frequent painful crisis)
72
management of sickle cell crisis
```
o Supportive – O2
o X match blood - Transfusion if Hb falls quickly
o Analgesia
o IV fluids
o Abx
```
73
pathophysiology of hemophilia
X-linked recessive
74
which factor is affected in haemophilia A
factor 8
75
which factor is affected in haemophilia B
factor 9
76
clinical features of haemophilia
* neonatal intracranial haemorrhage severe
* hemarthrosis bleeding into joint
* IM bleed
* excessive bruising upon learning to crawl and walk
* epitasis
* blood in urine
* blood in stool
* deep bruises
77
investigation for haemophilia
• Activated partial Thromboplastin time (aPTT) – inc
o use to test intrinsic pathway
• Factor 8 assay or 9 – level dec
• normal prothrombin time
o use to test extrinsic and common pathway
• plasma von Willebrand factor assay – normal to exclude VWF deficiency
• other factors assay – to exclude problems elsewhere
• FBC – normal, low after bleeding
• LFT – factor deficit can be caused by liver disease
• FHx or carrier – test baby’s gender from 9 wks, if male: plan safe delivery
o can do amniocentesis or CVS to confirm diagnosis
Management
78
management of ahaemophilia
o Avoid NSAIDs and IM injections
o Regular or prophylactic factor replacement therapy to those with severe haemophilia
Haemophilia A every 48hrs, for haemophilia B 2x week
Implantable port (from 2yrs) at home
o Minor bleeding – eg minor surgery/dential extraction
Pressure, elevation
IV desmopressin (0.3µg/kg/12hrs over 20min) to factor 8
desmopressin does not work in Hemophilia B
o Major bleeding (haemarthrosis etc.)
Aim to factor 8 to 50% of normal
o Life-threatening bleeding (e.g., airway obstructing)
Need 100% levels factor 8 (recombinant factor 8)
o PRICE
79
pathophysiology of thalaessmia
* autosomal recessive
* inherited microcystic anaemia caused by mutations of the beta-globin gene leading to dec or absent synthesis of beta-globin ineffective erythropoiesis.
80
where is thalassemia most common
-thalassaemia most common; Southeast Asian, middle east, Mediterranean backgrounds.
81
clinical features of thalassemia
• Severe haemolytic anaemia
• Compensatory BM hyperplasia characteristic overgrowth of facial + skull bones
• Haemosiderosis (iron overload) + cardiomyopathy, DM + skin pigmentation due to repeated blood transfusion.
o Less common since intro of desferrioxamine
• lethargy, abdo distension, FTT, low height and weight
• pallor
• spinal changes (iron overload osteopenia)
• hepatosplenomegaly
82
investigation for thalaessemia
• Hypochromic, microcytic anaemia in thalassaemia trait may be confused with iron def.
• Homozygous: severe hypochromic microcytic anaemia, bizarre fragmented poikilocytes and target cells.
• Diagnosis of type: Hb electrophoresis.
o ß-thalassaemia major: absence of HbA1, HbA2 + HbF
o normal ferritin
83
management of thalaessemia
• Thalassaemia trait requires no treatment.
• Thalassemia major: regular blood transfusions to maintain Hb levels.
o Haemosiderosis (iron overload) is inevitable consequence, can minimise by use of SC/IV infusions of chelating agent desferrioxamine.
o Or PO iron chelating agents
Year 5 Conditions
flashcards
Decks in class (19)
# Cards
